Literature DB >> 3973390

Growth cycle-dependent generation of complement-resistant Leishmania promastigotes.

E D Franke, P B McGreevy, S P Katz, D L Sacks.   

Abstract

The ability of in vitro grown Leishmania promastigotes to resist lysis by complement and survive in undiluted human serum was related to the species of Leishmania and the growth phase in culture. Promastigotes from log phase cultures were always killed in undiluted serum, whereas survival of stationary phase promastigotes varied among species. All L. major and L. m. amazonensis were killed, while up to 30% of L.b. panamensis and 10% of L. donovani survived. Lysis of promastigotes by human serum was inhibited in heat-inactivated serum and EDTA-chelated serum, indicating that activation of complement was responsible for killing. Therefore, during growth in vitro, some strains of Leishmania promastigotes can undergo development from a complement-susceptible to -resistant stage. Stationary phase promastigotes of L.b. panamensis which survived in undiluted human serum were capable of subsequent growth in culture, and were also able to initiate infection in Mystromys albicaudatus. Organisms selected on the basis of complement resistance were more infective for M. albicaudatus than either log phase promastigotes or unselected promastigotes from stationary cultures. These data support the notion that the life cycle of Leishmania includes an infective stage promastigote which is generated during growth within the sandfly and which, on inoculation, is able to survive the potentially lethal effect of normal serum before uptake by host macrophages.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3973390

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Characterization of a differentially expressed protein that shows an unusual localization to intracellular membranes in Leishmania major.

Authors:  E Knuepfer; Y D Stierhof; P G McKean; D F Smith
Journal:  Biochem J       Date:  2001-06-01       Impact factor: 3.857

2.  Differential surface deposition of complement proteins on logarithmic and stationary phase Leishmania chagasi promastigotes.

Authors:  Amanda E Ramer-Tait; Soi Meng Lei; Bryan H Bellaire; Jeffrey K Beetham
Journal:  J Parasitol       Date:  2012-06-04       Impact factor: 1.276

3.  Genomic organisation and expression of a differentially-regulated gene family from Leishmania major.

Authors:  H M Flinn; D F Smith
Journal:  Nucleic Acids Res       Date:  1992-02-25       Impact factor: 16.971

4.  Promastigote infectivity in Leishmania infantum.

Authors:  F Grimm; R Brun; L Jenni
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

Review 5.  Complement evasion by parasites: search for "Achilles' heel".

Authors:  Z Fishelson
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

6.  Cytolytic activity in the genus Leishmania: involvement of a putative pore-forming protein.

Authors:  F S Noronha; F J Ramalho-Pinto; M F Horta
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

7.  The ultrastructure of Leishmania major in the foregut and proboscis of Phlebotomus papatasi.

Authors:  R Killick-Kendrick; K R Wallbanks; D H Molyneux; D R Lavin
Journal:  Parasitol Res       Date:  1988       Impact factor: 2.289

8.  Purification of a Trypanosoma cruzi membrane glycoprotein which elicits lytic antibodies.

Authors:  K A Norris; G Harth; M So
Journal:  Infect Immun       Date:  1989-08       Impact factor: 3.441

9.  Kinetic analysis of ex vivo human blood infection by Leishmania.

Authors:  Inmaculada Moreno; Mercedes Domínguez; Darío Cabañes; Carmen Aizpurua; Alfredo Toraño
Journal:  PLoS Negl Trop Dis       Date:  2010-07-13

10.  Characterization of DNA sequences that confer complement resistance in Leishmania chagasi.

Authors:  Rebecca R Dahlin-Laborde; Eric J Scolaro; Nathan M Romine; Amanda E Ramer-Tait; Soi Meng Lei; Jeffrey K Beetham
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.